Immuneering Corporation
IMRX
$1.45
-$0.01-0.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.69M | 4.01M | 4.25M | 4.12M | 4.38M |
| Depreciation & Amortization | 7.30K | 7.30K | 7.30K | 7.30K | 7.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.56M | 15.27M | 14.91M | 15.33M | 16.30M |
| Operating Income | -18.56M | -15.27M | -14.91M | -15.33M | -16.30M |
| Income Before Tax | -18.05M | -14.60M | -14.08M | -14.31M | -15.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.05M | -14.60M | -14.08M | -14.31M | -15.08M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.05M | -14.60M | -14.08M | -14.31M | -15.08M |
| EBIT | -18.56M | -15.27M | -14.91M | -15.33M | -16.30M |
| EBITDA | -18.46M | -15.18M | -14.82M | -15.23M | -16.20M |
| EPS Basic | -0.58 | -0.49 | -0.47 | -0.49 | -0.52 |
| Normalized Basic EPS | -0.36 | -0.31 | -0.30 | -0.31 | -0.32 |
| EPS Diluted | -0.58 | -0.49 | -0.47 | -0.49 | -0.52 |
| Normalized Diluted EPS | -0.36 | -0.31 | -0.30 | -0.31 | -0.32 |
| Average Basic Shares Outstanding | 31.05M | 29.84M | 29.65M | 29.37M | 29.27M |
| Average Diluted Shares Outstanding | 31.05M | 29.84M | 29.65M | 29.37M | 29.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |